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Abstract
Increased production of plasminogen activator inhibitor-1 (PAI-1) in plaques plays a role in the pathogenesis of atherosclerosis. This study
was conducted to investigate the effect of blockade of Rho/Rho-kinase signaling on the synthesis of PAI-1 in cultured human peripheral
blood monocytes. HMG-CoA reductase inhibitors (statins) and inhibitors of Rho and Rho-kinase were added to monocyte cultures. The
levels of PAI antigen and mRNA were determined by Western blotting and RT-PCR, respectively, and PAI-1 expression was assessed by
immunohistochemistry. We performed pull-down assays to determine the activity of Rho by measuring the GTP-bound form of Rho A. In
unstimulated and lipopolysaccharide (LPS)-stimulated cultured monocytes, statins reduced the levels of PAI-1 antigen and mRNA. The
suppressive effects of statins on PAI-1 synthesis were reversed by geranylgeranylpyrophosphate (GGPP) and were mimicked by C3
exoenzyme. Immunohistochemistry confirmed the role of lipid modification by GGPP in suppressive effect of statins in PAI-1 synthesis.
Pull-down assays demonstrated that statins decreased the levels of the GTP-bound form of Rho A. Our findings suggest that statins decrease
the activity of Rho by inhibiting geranylgeranylation. Moreover, Rho-kinase inhibitors, Y-27632 and fasudil, suppressed the synthesis of PAI-
1 in this culture system. We show that inhibition of Rho/Rho-kinase signaling downregulates the synthesis of PAI-1 in human monocytes.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
In addition to an enhanced coagulation cascade, impaired
fibrinolysis is also an important determinant in thromboge-
nicity in coronary artery disease [1]. Plasminogen activator
inhibitor-1 (PAI-1) is a major physiological inhibitor of
fibrinolysis. Increased plasma PAI-1 levels are associated
with coronary events although it is unclear whether its
elevation is a cause or a result of thrombus formation [2–
4]. Since PAI-1 is one of the serine protease inhibitors, it is
also involved in intimal thickening, leading to the progres-
sion of atherosclerosis [2,5,6]. We recently have shown
increased PAI-1 levels in coronary plaques of acute coro-
nary syndromes compared to stable plaques [7].
Macrophage infiltration plays a pivotal role in the genesis
of coronary artery disease related to atherosclerosis, and
plaque macrophages appear to be derived from peripheral
blood monocytes [8–11]. In addition to endothelial and
smooth muscle cells, PAI-1 is also expressed by peripheral
blood monocytes and plaque macrophages[12–16]. We
recently showed that blockade of the renin–angiotensin
system by an angiotensin-converting enzyme inhibitor
reduces the synthesis of PAI-1 in cultured human monocytes
[17]. Thus, controlling PAI-1 production by monocytes and
macrophages may be a target for treating coronary artery
disease.
Statins inhibit HMG-CoA reductase, a rate-limiting
enzyme in the mevalonate pathway, which catalyzes the
reduction of HMG-CoA to mevalonate. Geranylgeranylpyr-
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ophosphate (GGPP) and farnesylpyrophosphate (FPP) are
downstream isoprenoids derived from mevalonate and they
contribute to lipid modification for signaling molecules such
as small and heterotrimeric GTP-binding proteins [18,19].
This lipid modification is critical for their functions. Thus,
statins can modulate the functions of these signaling mol-
ecules.
Recent studies have shown that HMG-CoA reductase
inhibitors cause a reduction in the synthesis of PAI-1 in
cultured myocytes and endothelial cells and that C3
exoenzyme, a specific Rho inhibitor, also suppresses the
synthesis of PAI-1 [20,21]. However, there are several
effectors of Rho proteins and it is not clear which pathway
downstream of Rho is important in PAI-1 synthesis.
Miyata et al. [22] recently showed that chronic treatment
with monocyte chemoattractant protein-1 (MCP-1) and
oxidized low density lipoprotein from adventitia caused
macrophage accumulation and migration in coronary
arteries, which was markedly inhibited by a Rho-kinase
inhibitor. These observations suggest that Rho/Rho-kinase
signaling plays a role in monocyte/macrophage function in
atherogenesis.
In the present study, we show that inhibition of Rho/Rho-
kinase signaling by statins and inhibitors of Rho and Rho-
kinase suppress the synthesis of PAI-1 in cultured human
monocytes and lipid modification by GGPP plays an im-
portant role in the activation of Rho.
2. Materials and methods
2.1. Materials
The sources of most of the conventional reagents for the
present study have been previously described [11,17].
Cerivastatin and pravastatin were kindly provided by Bayer
Ltd. (Leverkusen, Germany) and Sankyo Pharmaceutical
Co. (Tokyo), respectively. C3 exoenzyme, which inhibits
Rho proteins by ADP-ribosylation on asparagine-41 in the
effector region of the GTPase, was obtained from Upstate
Biotechnology (Lake Placid, NY). Rho-kinase inhibitors,
Y-27632 and fasudil, were generously obtained from Wel-
fide Co. (Osaka, Japan) and Asahi Chemical Industry Co.
(Osaka, Japan), respectively [23,24]. Human lipoprotein
deficient serum (LPDS) was prepared by ultracentrifugation
as previously described [25].
2.2. Isolation of human peripheral blood monocytes
The method of isolation of peripheral blood mononuclear
cells from healthy volunteers was performed as previously
described [17,26]. Briefly, peripheral blood mononuclear
cells were isolated by gradient centrifugation and plastic
adherent methods. Monocytes were obtained by scraping
into cold medium and were characterized by flow cytometry
and cytohistochemistry. Flow cytometry showed that the
isolated cells from seven preparations had CD14
(94.3F 4.2%) and CD 36 (92.6F 4.1%) antigens and neg-
ligible contamination with CD3 (0.4F 0.3%) or CD19
(0.3F 0.2%). Cytohistochemistry revealed that almost
100% of the cells stained positive with a-naphtyl-butyrate
esterase. These monocytes were used for all the experi-
ments. Ethical approval was obtained for the study and
informed consent for experimental examinations of periph-
eral blood was obtained from all the volunteers.
2.3. Culture conditions and experimental design
Monocytes were cultured in RPMI 1640 medium
(Gibco, Grand Island, NY) containing 2 mg/ml LPDS.
The levels of PAI-1 protein and mRNA in cells were
determined by Western blotting and reverse transcriptase
polymerase chain reaction (RT-PCR). We treated the cells
with various concentrations of cerivastatin (0.005–0.1
Amol/l) and pravastatin (2–100 Amol/l) for RT-PCR and
Western blotting, whereas we used the concentrations of
0.01 Amol/l cerivastatin and 2 Amol/l pravastatin for immu-
nohistochemical staining. To examine the effect of statins
on isoprenylation, 200 Amol/l mevalonic acid lactate, 5
Amol/l GGPP or 5 Amol/l FPP was added to the cultures in
the presence of cerivastatin or pravastatin. In some experi-
ments, monocytes were preincubated with 1 Ag/ml lip-
opolysaccharide (LPS) for 30 min at 37 jC and washed
three times, and then 0.05 Amol/l cerivastatin or 20 Amol/l
pravastatin was added to the cultures. After 1 day of
culture, Western blotting was performed. To clarify the role
of Rho and Rho-kinase in the synthesis of PAI-1, we treated
cells with C3 exoenzyme (5 Ag/ml), 10 Amol/l Y-27632 or
fasudil and performed RT-PCR, Western blotting and
immunohistochemistry.
Viable cells were counted by trypan blue exclusion after
3 days of culture as previously described [27]. The viability
of cultured nontreated monocytes was 98.7F 1.2% and
there were no significant differences in viability between
control cells and those treated with 0.05 Amol/l cerivastatin,
20 Amol/l pravastatin, 5 Ag/ml C3 exoenzyme, 10 Amol/l
Y-27632 or 10 Amol/l fasudil (n = 7, each).
2.4. Western blotting
Western blotting was performed as previously described
[17]. The treated cells were collected and solubilized with a
lysis buffer (10 mmol/l Tris, 2 mmol/l EDTA, 20 Ag/ml
antipain, 20 Ag/ml leupeptin, 1 Amol/l DTT and 1 Amol/l
PMSF), and the protein concentrations in the lysates were
measured by the Bradford method [28]. Aliquots containing
20 Ag of protein were subjected to SDS/polyacrylamide gel
electrophoresis and the proteins were then transferred onto
polyvinylidene difluoride membranes (Millipore, Bedford,
MA). After incubating with blocking solution at room
temperature for 30 min, the membranes were incubated
for 60 min at room temperature with a rabbit polyclonal
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antibody to human PAI-1 diluted 1:500 (Molecular Innova-
tion Inc., Royal Oak, MI). After three washes, the mem-
branes were incubated for 45 min at room temperature with
horseradish peroxidase-conjugated goat anti-rabbit IgG
diluted 1:10,000 (Santa Cruz Biotechnology Inc., Santa
Cruz, CA). The signals from immunoreactive bands were
visualized by fluorography with an Amersham ECLk
System (Amersham Pharmacia Biotech UK Lit, Bucking-
hamshire, England).
2.5. Levels of PAI-1 mRNA
RT-PCR was performed as previously described [17,26].
Total RNA from cultured monocytes was prepared using
ISOGEN (Nippon Gene, Toyama, Japan). Reverse transcrip-
tase reactions were performed using an RNA PCR (AMV)
Version 2.1 kit (Takara Shuzo Co., Ltd., Otsu, Japan).
Reverse transcription was conducted in an 80-Al reaction
mixture containing 10 mmol/l Tris–HCl (pH 8.3), 50 mmol/l
KCl, 5 mmol/l MgCl2, 1 mmol/l of each deoxynucleotide
triphosphate, 2.5 Amol/l random hexamer, 1 U/Al RNAase
inhibitor and 0.25 U/Al avian myeloblastosis virus reverse
transcriptase. Ten microliters of reverse-transcribed material
was amplified (1.5 U Takara Taqk) using a primer pair
specific to human PAI-1 (forward primer, 5V-GAGGT-
GCCTCTCTCTGCCCTCACCAACATT-3V; reverse primer,
5V-AGCCTGAAACTGTCTGAACATGTCG-3V). The PCR
product was 185 bp. PCR consisted of 30 cycles at 95 jC for
1.2 min, 62 jC for 1 min and 72 jC for 1 min. The primers
used for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) were as follows: forward primer, 5V-CGTCA-
TGGGTGTGAACCATGAGAAG-3V; reverse primer, 5V-
GCATGGACTGTGGTCATGAGTCCTT-3V. The PCR
product was 147 bp and the reaction cycles for PCR were
95 jC for 1 min, 64 jC for 1 min and 72 jC for 1 min for 28
cycles. The RT-PCR-amplified samples were visualized on
2% agarose gels using ethidium bromide.
2.6. Immunohistochemistry
Isolated monocytes were cultured for 5 days in the
presence or absence of statin onto chamber slides (Nalge
Nunc International, Naperville, IL). After fixation for 15
min with 4% paraformaldehyde (Merck, Frankfurt) in phos-
phate buffer, pH 7.2, and washing with PBS, immunohis-
tochemistry was performed as previously described [11,29].
Slides were reacted at room temperature for 60 min with a
monoclonal antibodies against human PAI-1 (American
Diagnostica Inc., Greenwich, CT) and for 30 min with a
biotinylated rabbit F(abV)2 IgG against mouse IgG (Dako,
Carpinteria, CA). A streptavidin-biotinylated horseradish
peroxidase system (StreptABComplex/HRP, Dako) was
used and antibody binding was visualized with 3,3V-diami-
nobenzidine (Dako) and hydrogen peroxide. The slides were
counterstained with hematoxylin.
2.7. Determination of the activity of Rho
Rho A activity was determined by measuring GTP-Rho
using the Rho-binding domain of rhotekin as previously
Fig. 1. Western blots (20 Ag of protein/lane) showing the effects on PAI-1
protein in monocytes of various concentrations of cerivastatin (A) and
pravastatin (B) after 2 days of culture. (A) Lane 1, control; lane 2, 0.005
Amol/l; lane 3, 0.01 Amol/l; lane 4, 0.05 Amol/l; and lane 5, 0.1 Amol/l. (B)
Lane 1, control; lane 2, 2 Amol/l; lane 3, 20 Amol/l; and lane 4, 100 Amol/
l. Results are from an experiment representative of four similar experi-
ments.
Fig. 2. Effect of statins on the cellular levels of PAI-1 protein in cultured
monocytes stimulated with 1 Ag/ml LPS. Monocytes were preincubated
with 1 Ag/ml LPS for 30 min, washed three times, and then cultured for 1
day in the presence of 0.05 Amol/l cerivastatin or 20 Amol/l pravastatin.
Lane 1, unstimulated monocytes; lane 2, LPS-stimulated monocytes; lane 3,
LPS-stimulated monocytes plus 0.05 Amol/l cerivastatin; and lane 4, LPS-
stimulated monocytes plus 20 Amol/l pravastatin. Results are from an
experiment representative of three similar experiments.
Fig. 3. Effects of GGPP and FPP on the reduced levels of PAI-1 mRNA and
protein induced by pravastatin in cultured monocytes as determined by RT-
PCR (A) and Western blotting (B). Lane 1, control; lane 2, 20 Amol/l
pravastatin; lane 3, 20 Amol/l pravastatin plus 5 Amol/l GGPP; lane 4, 20
Amol/l pravastatin plus 5 Amol/l FPP. GAPDH indicates glyceraldehyde-3-
phosphate dehydrogenase. Results are from an experiment representative of
four similar experiments.
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described [30]. Briefly, the cells treated with or without 0.05
Amol/l cerivastatin or 20 Amol/l pravastatin were extracted
with a lysis buffer (50 mmol/l Tris, pH 7.2, 500 mmol/l NaCl,
10 mmol/l MgCl2, 1% Triton X-100, 0.5% sodium deoxy-
cholate, 0.1% SDS, 20 Ag/ml antipain, 20 Ag/ml leupeptin, 1
Amol/l PMSF). After centrifugation at 12,000 g for 10 min
at 4 jC, the extracts were incubated for 45 min at 4 jC with
glutathione-Sepharose 4B beads coupled with glutathione-S-
transferase (GST)–rhotekin fusion protein. The beads were
washed three times with a washing buffer (50mmol/l Tris, pH
7.2, 150 mmol/l NaCl, 10 mmol/l MgCl2, 1% Triton X-100,
20 Ag/ml antipain, 20 Ag/ml leupeptin, 1 Amol/l PMSF) and
boiled for 5 min in a loading buffer. Bound Rho A proteins
were quantitatively determined by Western blotting using a
mouse monoclonal antibody to Rho A diluted 1:500 (Santa
Cruz Biotechnology).
2.8. Immunoassays of PAI-1
ELISA assay was performed as previously described
[17]. The concentrations of PAI-1 in culture supernatants
were measured by a commercially available ELISA kit
(TintElizeR PAI-1, Biopool, Umea, Sweden) in accordance
with the manufacturer’s instructions.
2.9. Statistical analysis
Statistical analysis was performed using ANOVA with
Scheffe´’s post hoc test, as appropriate. A level of P < 0.05
was considered significant. Data are expressed as means
F S.D.
3. Results
3.1. Effect of statins on the levels of PAI-1 protein
Western blotting was used to examine the effects on PAI-
1 protein of various concentrations of cerivastatin and
pravastatin after 2 days of culture (Fig. 1A and B). Although
cerivastatin reduced the levels of PAI-1 protein, its effect
was not concentration-dependent (Fig. 1A). Even 0.005
Amol/l cerivastatin significantly reduced the levels of PAI-
1 protein in cultured monocytes (Fig. 1A, lane 2). Pravas-
tatin at 2 Amol/l significantly decreased the levels of PAI-1
protein in cultured monocytes and decreased them further at
100 Amol/l (Fig. 1B). The levels of PAI-1 antigen in the
culture media of monocytes were significantly decreased by
cerivastatin (0.01 Amol/l) and pravastatin (2 Amol/l) (n = 5,
P < 0.05, each), and there was no significant difference
between the effects of 0.01 Amol/l cerivastatin and 2
Amol/l pravastatin (data not shown).
In addition, we examined the effect of statins on the
levels of PAI-1 protein in monocytes stimulated for 30 min
with 1 Ag/ml LPS. After washing, monocytes were cultured
for 24 h in the presence of statins. Cerivastatin and pravas-
tatin reduced the levels of PAI-1 protein (Fig. 2).
3.2. Involvement of inhibition of geranylgeranylation in the
suppressive effect of statins
To determine which isoprenylation was inhibited by
statins, we added 5 Amol/l GGPP or 5 Amol/l FPP to the
cultures in the presence of 20 Amol/l pravastatin. RT-PCR
and Western blotting revealed that GGPP, but not FPP,
reversed the suppressive effects of 20 Amol/l pravastatin
on the levels of PAI-1 mRNA and protein (Fig. 3A and B).
Similar results were obtained with cells treated with 0.05
Amol/l cerivastatin (data not shown). These observations
suggest that the suppressive effect of statins on PAI-1 syn-
Fig. 4. Effect of C3 exoenzyme (5 Ag/ml) on the levels of PAI-1 mRNA (A)
and protein (B) in cultured monocytes. Lane 1, control; lane 2, 5 Ag/ml C3
exoenzyme. Results are from an experiment representative of three similar
experiments.
Fig. 5. Photomicrographs showing the expression of PAI-1 by human monocytes after 5 days of culture in the presence of 0.01 Amol/l cerivastatin, 2 Amol/l
pravastatin or 5 Ag/ml C3 exoenzyme. After fixation for 15 min with 4% paraformaldehyde in phosphate buffer, pH 7.2 and three washes, slides were reacted at
room temperature for 60 min with a monoclonal antibody against human PAI-1 and for 30 min with a biotinylated rabbit F(abV)2 IgG against mouse IgG. A
streptavidin-biotinylated horseradish peroxidase system was used and antibody binding was visualized with 3,3V-diaminobenzidine and hydrogen peroxide. The
slides were counterstained with hematoxylin. (A) Control; (B) Cerivastatin; (C) Pravastatin; (D) C3 exoenzyme. Original magnification,  1000.
Fig. 6. Photomicrographs showing the effect of GGPP on the reduced expression of PAI-1 induced by pravastatin (A, control; B, 2 Amol/l pravastatin; C, 2
Amol/l pravastatin plus 5 Amol/l GGPP; D, 2 Amol/l pravastatin plus 5 Amol/l FPP). GGPP or FPP was added to the monocytes in the presence of 2 Amol/l
pravastatin and cultured for 5 days. The staining procedure is described in the legend of Fig. 5. Original magnification,  1000.
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thesis in cultured monocytes is mediated by inhibition of
geranylgeranylation.
3.3. Effect of Rho inhibition on PAI-1 synthesis
Among the geranylgeranylated signaling proteins, we
attempted to examine the role of Rho in PAI-1 synthesis.
C3 exoenzyme (5 Ag/ml), a specific Rho inhibitor, decreased
the levels of PAI-1 mRNA and protein in the cells after 1 day
of culture (Fig. 4A and B).
3.4. PAI-1 expression in cultured monocytes
Immunohistochemical staining demonstrated that both
cerivastatin and pravastatin suppressed the expression of
PAI-1 in monocytes cultured for 5 days (Fig. 5A–C). C3
exoenzyme (5 Ag/ml) also decreased the expression of PAI-
1 in cultured monocytes (Fig. 5D). The suppressive effect of
2 Amol/l pravastatin (Fig. 6B) on PAI-1 expression was
reversed by GGPP (Fig. 6C), but not by FPP (Fig. 6D).
Similar results were obtained with 0.01 Amol/l cerivastatin
(data not shown).
Fig. 7. Immunoblot showing the effect of statins on the activity of Rho A.
Isolated monocytes were cultured for 6 h in the presence or absence of 0.05
Amol/l cerivastatin or 20 Amol/l pravastatin. A pull-down assay using GST-
Rhotekin bound to glutathione-Sepharose 4B beads was performed as
described in Section 2. The amounts of the GTP-bound form of Rho Awere
quantitated by Western blotting. Lane 1, control; lane 2, 0.05 Amol/l
cerivastatin; and lane 3, 20 Amol/l pravastatin. Similar results were obtained
in three independent experiments.
Fig. 8. Effect of 10 Amol/l Y-27632 and fasudil on the reduced levels of
PAI-1 mRNA as determined by RT-PCR [(A) Lane 1, control; lane 2, 10
Amol/l Y-27632; lane 3, 10 Amol/l fasudil]. Results are from an experiment
representative of four similar experiments. Effect of various concentrations
of Y-27632 (B) and fasudil (C) on the cellular levels of PAI-1 protein in
cultured monocytes. Lanes 1, control; lanes 2, 0.1 Amol/l; lanes 3, 1 Amol/l;
and lanes 4, 10 Amol/l. Results are from an experiment representative of
four similar experiments.
Fig. 9. Photomicrographs showing the effect of Rho-kinase inhibitors on
PAI-1 expression in cultured monocytes. (A) Control; (B) Y-27632 (10
Amol/l); (C) Fasudil (10 Amol/l). The staining method is described in the
legend of Fig. 5. Original magnification,  1000.
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3.5. Effect of statins on Rho activation
To clarify the association of the suppressive effect of
statins with Rho activation, we determined the activity of
Rho A by a pull-down assay after 6 h of culture. Both 0.05
Amol/l cerivastatin and 20 Amol/l pravastatin markedly
decreased the levels of the GTP-bound form of Rho A
(Fig. 7), providing direct evidence that statins downregulate
the activity of Rho in cultured monocytes.
3.6. Effect of Rho-kinase inhibitors on PAI-1 synthesis
Among the effectors of Rho, we examined the involve-
ment of Rho-kinase in the synthesis of PAI-1. RT-PCR
demonstrated that Y-27632 (10 Amol/l, Fig. 8A, lane 2)
and fasudil (10 Amol/l, Fig. 8A, lane 3) suppressed the
levels of PAI-1 mRNA in monocytes after 1 day of culture.
Y-27632 abolished the reversing effect of GGPP on the
reduced levels of PAI-1 mRNA induced by 0.05 Amol/l
cerivastatin (data not shown). Western blotting showed the
effect on PAI-1 protein of various concentrations of Y-
27632 (Fig. 8B) and fasudil (Fig. 8C). Immunohistochem-
ical staining confirmed that both Y-27632 (10 Amol/l, Fig.
9B) and fasudil (10 Amol/l, Fig. 9C) suppressed the expres-
sion of PAI-1 after 5 days of culture.
4. Discussion
The present study shows that inhibition of Rho/Rho-
kinase signaling downregulates the synthesis of PAI-1 in
human monocytes, suggesting that Rho and Rho-kinase are
involved in the synthesis of PAI-1 in monocytes. Our data
also show that cerivastatin and pravastatin suppress the
synthesis of PAI-1, independent of cholesterol-lowering,
probably mediated via inactivation of Rho as determined
by measuring the GTP-bound form of Rho A.
Our results showed that GGPP, but not FPP, abolished
the effects of cerivastatin and pravastatin on the synthesis of
PAI-1 as determined by RT-PCR, Western blotting and
immunohistochemical staining. Park et al. and Essig et al.
[20,21] reported the same effect of statins on PAI-1 syn-
thesis using cultured embryonic chicken atrial cells and
simian virus 40-transformed rat endothelial cells. These
findings suggest that statins suppress PAI-1 synthesis via
inhibition of geranylgeranylation of a signaling molecule(s)
and that a geranylgeranylated protein is involved in the
regulation of PAI-1 synthesis. Therefore, we focused on
Rho which is among the geranylgeranylated small GTPases.
Rho activation consists of gerenylgeranylation from a
pool of unprocessed Rho, a GDP/GTP exchange and trans-
location to membranes. Our pull-down assay demonstrated
that statins decreased the levels of the GTP-bound form of
Rho A in cultured monocytes. This is direct evidence that
statins inactivate Rho probably by preventing gerenylger-
anylation, suggesting that statins downregulate the synthesis
of PAI-1 via inactivation of Rho. Moreover, C3 exoenzyme,
a specific Rho inhibitor [31], suppressed the synthesis of
PAI-1 in cultured monocytes. Together, Rho might play a
role in PAI-1 synthesis.
There are a number of Rho targeting molecules, includ-
ing Rho-kinase/ROKa/ROCKII, ROKh/ROCKI, protein
kinase N, rhophilin, rhotekin, citron and p140mDia
[32,33]. Among these effectors, Rho-kinase is involved in
smooth muscle contraction, stress fiber formation, focal
adhesion formation, neurite retraction and cytokinesis. With
regard to the relationship between monocytes/macrophages
and Rho-kinase, it has been shown that Rho-kinase is
involved in the macrophage-mediated formation of coronary
vascular lesions in vivo in pigs and in the chemotaxis
mediated by MCP-1 in THP-1 cells in vitro [22,34]. In
the present study, Y-27632 and fasudil suppressed the syn-
thesis of PAI-1 in cultured monocytes freshly isolated from
human blood. This is the first demonstration that blockade
of Rho-kinase downregulates the synthesis of PAI-1 in the
monocyte/macrophage lineage. We also showed that the
restoring effect of GGPP on the reduced levels of PAI-1
induced by statins was abrogated by Y-27632. These find-
ings suggest that Rho-kinase is responsible for the regula-
tion of PAI-1 synthesis to some degree.
The idea that Rho and Rho-kinase play a role in PAI-1
synthesis is consistent with the results of previous studies
using vascular smooth muscle and endothelial cells and
myocytes [20,21,35,36]. The effects of statins, C3 exoen-
zyme and Rho-kinase inhibitors on various molecules have
been demonstrated by immunoassays, RT-PCR and North-
ern and Western blotting. In addition to these method-
ologies, in the present study immunohistochemical
staining clearly showed that expression of PAI-1 was
reduced by statins, C3 exoenzyme and Rho-kinase inhib-
itors and that the decreased PAI-1 expression caused by
statins was reversed by GGPP in cultured peripheral blood
monocytes, indicating the role of geranylgeranylation in the
suppressive effect of statins on PAI-1 synthesis.
Recent studies demonstrated that treatment with pravas-
tatin in the acute phase after the onset of acute myocardial
infarction in patients with average cholesterol levels resulted
in a better outcome compared with a placebo group [37],
and that pravastatin induced an antithrombotic effect inde-
pendent of cholesterol-lowering in patients with hyperlipi-
demia [38], suggesting a direct action of pravastatin on the
vascular wall rather than a cholesterol-lowering effect.
Since, as described above, PAI-1 plays a role in the develop-
ment of atherosclerosis and vascular thrombogenicity, our
results support the benefit of using pravastatin to treat
coronary artery disease [39–41].
Suzuki et al. [42] reported that Y-27632 and fasudil
inhibited the activation of Rho-kinase and the resultant
phosphorylation of myosin-binding subunit induced by
relatively weak agonists in platelet activation. Moreover,
Toshima et al. [43] showed that fasudil reduced the area of
cerebral infarction in a stroke animal model induced by
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microthrombi. With respect to treatment of thrombogenicity,
the present study suggests that Rho-kinase inhibitors may be
beneficial for improving impaired fibrinolysis.
In conclusion, the present study shows that inhibition of
Rho/Rho-kinase suppresses PAI-1 synthesis in cultured
human monocytes, suggesting that this may be a viable
approach for treating coronary artery disease.
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